Semaphorin 3B (SEMA3B) is a secreted axonal guidance molecule that is expressed during development and throughout adulthood. Recently, SEMA3B has emerged as a tumor suppressor in non-neuronal cells. Here, we show that SEMA3B is a direct target of GATA3 transcriptional activity. GATA3 is a key transcription factor that regulates genes involved in mammary luminal cell differentiation and tumor suppression. We show that GATA3 relies on SEMA3B for suppression of tumor growth. Loss of SEMA3B renders GATA3 inactive and promotes aggressive breast cancer development. Overexpression of SEMA3B in cells lacking GATA3 induces a GATA3-like phenotype and higher levels of SEMA3B are associated with better cancer patient prognosis. Moreover, SEMA3B interferes with activation of LIM kinases (LIMK1 and LIMK2) to abrogate breast cancer progression. Our data provide new insights into the role of SEMA3B in mammary gland and provides a new branch of GATA3 signaling that is pivotal for inhibition of breast cancer progression and metastasis.
INTRODUCTION
Semaphorins function as short-range axonal guidance molecules. 1 There are eight classes of semaphorins, and class-3 semaphorins are the only secreted group in vertebrates. 2 Within class-3, there are seven semaphorin members that belong to semaphorin/ collapsin family and exert their cellular effects through binding to neuropilins and plexin receptor family members. 2, 3 Semaphorin 3B (SEMA3B) is a secreted molecule that contains a highly conserved Sema domain in the amino terminus. Interaction between semaphorins and their receptors leads to changes in cytoskeletal architecture and cellular motility through influencing the activation state of various Rho GTPases in a targeted cell. [4] [5] [6] [7] [8] [9] Semaphorins along with other axonal guidance molecules function as environmental cues to allow proper innervation of neurons by either permitting or inhibiting their growth, thereby guiding neurites migration along a correct path during nervous system development.
Although SEMA3B was initially discovered as an inhibitory axonal guidance molecule, recent findings suggest that SEMA3B also functions as a tumor suppressor in lung, renal, gastric and potentially breast tissues. [10] [11] [12] [13] [14] In the mammary gland, SEMA3B is present in both luminal and basal epithelial cells. 3 However, the importance of SEMA3B in maintenance of mammary epithelial cell homeostasis remains unclear.
Along with others, we previously showed that GATA3 is essential for driving mammary epithelial cell differentiation and maintaining mammary gland homeostasis. [15] [16] [17] [18] GATA3 belongs to GATA family of transcription factors that have fundamental roles as master regulators of cellular differentiation and homeostasis in various tissues. 15, [19] [20] [21] [22] The GATA family comprises six members that are expressed in a tissue-specific manner. 23 All GATA family members contain two transactivation domains in the amino terminus and two conserved zinc-finger domains at the carboxyl terminus. In addition to their structural similarities, GATA family members recognize and bind to a consensus DNA sequence (A/T) GATA(A/G) to regulate downstream target genes. 24 Loss of or mutations in GATA3 results in development of aggressive breast cancer. [25] [26] [27] [28] [29] [30] Indeed, GATA3 is one of the top three mutated genes in breast cancer patients, 16 emphasizing its importance in tumor development. Therefore, identifying new GATA3 downstream target genes provides valuable information in discovering new cancer biomarkers and potential therapeutic strategies for prevention of breast cancer.
In this study, we establish SEMA3B as a new GATA3 downstream target gene that is indispensible for GATA3 tumorsuppressive activity. In the absence of GATA3, elevated SEMA3B levels independently interfere with aggressive tumor growth and higher SEMA3B levels is associated with better breast cancer patient prognosis. We also show that SEMA3B interferes with activation of LIM kinases (LIMK1 and LIMK2) that are known Rho GTPases downstream targets. Inhibition of LIMK1/2 activation provides a molecular mechanism for inhibition of breast cancer progression via SEMA3B. Our findings highlight the importance of SEMA3B as a GATA3 downstream target gene and provide a new mechanism for driving tumor suppression in mammary epithelial cells.
RESULTS

In silico analysis of breast cancer patient samples demonstrates a correlation between expression of GATA3 and SEMA3B
We initially performed in silico gene expression analysis by utilizing the Cancer Genome Atlas (TCGA) and the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) databases to determine the global gene expression alterations that correlate with changes in GATA3 levels. Gene expression analysis of 597 breast cancer samples, as well as RNAseq analysis of 1215 tumor samples from TCGA database indicated a strong correlation between loss of GATA3 and downregulation of SEMA3B (Figure 1a and Supplementary Figures 1 and 2) . To demonstrate the validity of our analysis, we also included the expression analysis of a pro-tumor gene MYC that is upregulated in the absence of GATA3 expression ( Figure 1a ). TCGA database analysis using Regulome Explorer (http://www.cancerregulome. org/) indicated that SEMA3B resides in the same protein network as GATA3 and several other key proteins such as BCL2, ESR1, CCNB1 and AR (Figure 1b ) and suggested a possible link between GATA3 levels and SEMA3B expression during breast cancer development.
To investigate a potential role for SEMA3B in breast cancer development, we performed analysis using a public microarray data set (GSE9014). The data suggest that SEMA3B is significantly downregulated in the samples from patients with invasive breast carcinoma ( Figure 1c ). Similarly, comparison of SEMA3B expression in normal versus triple-negative breast cancer samples using the TCGA database also indicated significant SEMA3B downregulation in triple-negative breast cancer patients ( Figure 1d ). We also examined SEMA3B levels across PAM50 breast cancer subtypes using METABRIC database ( Figure 1e ) showing that SEMA3B levels remain high in luminal cancers. However, SEMA3B levels decreases significantly in basal subtypes ( Figure 1e ). This analysis in PAM50 subtypes reinforces the importance of SEMA3B and suggests a correlation between the loss of GATA3 and SEMA3B levels during aggressive breast cancer formation. Moreover, there was a correlation between SEMA3B and breast cancer progression, with decreasing expression levels of SEMA3B as the tumors progress from stage I to stage IV (Supplementary Figure 3) . We observed a similar trend in downregulation of SEMA3B expression when we compared low-grade tumors with highergrade tumors in the affected patients ( Supplementary Figure 4) . Finally, analysis of the van't Veer breast cancer database for breast cancer survival outcome 31 indicated a poorer prognosis for patients with lowered SEMA3B expression ( Figure 1f ). Collectively, the in silico analysis of breast cancer patient samples provides clues to a potential role for SEMA3B during breast cancer development and suggests an interplay between GATA3 and SEMA3B. 
GATA3 directly controls SEMA3B expression
To decipher whether GATA3 directly or indirectly controls SEMA3B levels, we performed in silico analysis using the ENCODE ChIP-Seq database. We searched for potential promoter sequences that contain a GATA3-binding site and found that the SEMA3B promoter is a potential target of GATA3 (Supplementary Figure 5 ). We then performed chromatin immunoprecipitation (ChIP) analysis in three different transiently transfected mammary cell lines, EpH4.9, T47D and MDA-MB-231 to examine whether GATA3 directly targets SEMA3B promoter. We found that in all these cell lines, GATA3 binds to the SEMA3B promoter ( Figure 2a ). Next, we overexpressed GATA3 in MDA-MB-231 cells and monitored alterations in SEMA3B expression levels. The control MDA-MB-231 cells exhibited minimal GATA3 and SEMA3B expression. However, overexpression of GATA3 resulted in significant upregulation of SEMA3B in the MDA-MB-231 cells (Figures 2b and c ).
In addition, immunostaining analysis demonstrated higher SEMA3B levels in cells overexpressing GATA3 when compared with control cells (Figure 2d ).
To study the GATA3 signaling pathway, we examined the relationship between GATA3 and SEMA3B in NMuMG cells that exhibit high levels of endogenous GATA3 expression. Knockdown of endogenous GATA3 levels using a specific small interfering RNA (siRNA) resulted in lowering SEMA3B expression levels, suggesting a correlation between GATA3 and SEMA3B levels in mammary cells (Figure 2e ). Taken together, these data indicate that in mammary epithelial cells, GATA3 directly binds to SEMA3B promoter and positively regulates SEMA3B expression.
GATA3 relies on intact SEMA3B expression to inhibit cellular migration and proliferation
To investigate the interplay between GATA3 and SEMA3B, we generated multiple MDA-MB-231 stable cell lines that either expressed the control short hairpin RNA MDA-MB-GATA3-PLKO (MDA-GATA3) or short hairpin RNA targeting SEMA3B (MDA-GATA3-SEMA3B KD ). In two-dimensional culture, cells overexpressing GATA3 lost their spindle-like morphology and became more cuboidal (luminal epithelial-like) (Figure 3a ), as we described previously. 32 Moreover, the MDA-GATA3 cells formed tight colonies as opposed to the more dispersed colonies of control cells (Figure 3a ). Intriguingly, in the absence of SEMA3B, the GATA3-overexpressing cells reverted to spindle-like morphology and resembled MDA-MB-231 (control) colonies that lacked GATA3 expression ( Figure 3a ).
We also examined the effect of SEMA3B overexpression independent of GATA3 signaling in MDA-MB-231 cells. As SEMA3B is downstream of GATA3, we were interested to determine whether SEMA3B could mimic GATA3 activity. Therefore, we generated MDA-MB-231 cells that either contained the control plasmid, MDA-MB-231-pEIZ (Control) or overexpressed SEMA3B, MDA-MB-231-SEMA3B (MDA-SEMA3B). Upon overexpression SEMA3B alone, MDA-MB-231 cells mimicked GATA3overexpressing cells and formed tight cuboidal colonies (Figures 3b and c) . To show that these observations are not exclusive to MDA-MB-231 cells, we examined the effect of SEMA3B knockdown in EpH4.9 mammary epithelial cells. EpH4.9 cells have detectable endogenous GATA3 and SEMA3B levels and in threedimensional Matrigel cultures form dense colonies that exhibit minimal invadopodia. Again, knockdown of SEMA3B in EpH4.9 cells resulted in formation of aggressively invasive colonies when compared with control ( Supplementary Figure 6) . These observations indicate that SEMA3B has a significant role in disrupting cellular invasiveness in mammary epithelial cell. Furthermore, GATA3 signaling requires intact SEMA3B to disrupt the invasive phenotype observed in MDA-MB-231 cells. Next, we examined the effect of SEMA3B on expression levels of epithelial to mesenchymal transition (EMT)-associated genes. As SEMA3B inhibits cellular invasiveness and reduction in SEMA3B levels forms invasive colonies, it is possible that the SEMA3B could modulate EMT-associated genes. qRT-PCR analysis in control and MDA-SEMA3B cells indicated that SEMA3B expression leads to reduction of the EMT genes Vimentin, Fibronectin, Snail and N-Cadherin expression levels (Figure 3d ), whereas, SEMA3B increases E-cadherin expression ( Figure 3d ). These results suggest that SEMA3B increases cell-cell interaction by lowering EMT genes and increasing E-cadherin levels.
To examine the effect of GATA3/SEMA3B signaling on MDA-MB-231 cell motility, we performed a scratch assay. MDA-MB-231 (control) cells were able to close the generated gap within 24 h (Figures 3e and f) . However, MDA-MB-231 cells expressing either GATA3 or SEMA3B failed to fill the gap within the same time span (Figures 3e and f) . The observation suggests that GATA3 and SEMA3B interfere with cellular migration in MDA-MB-231 cells. Interestingly, MDA-GATA3-SEMA3B KD cells closed the generated gap, similar to MDA-MB-231 parental cells, within 24 h (Figure 3d ). These data suggest that GATA3 signaling relies on the presence of SEMA3B to inhibit cellular migration. As SEMA3B functions as a short-range secreted molecule, we asked whether SEMA3B could also function via paracrine manner in mammary cells. We examined MDA-MB-231 cell migration using a transwell assay in presence of either control or SEMA3Bconditioned medium. We observed significantly less cellular migration in response to SEMA3B-conditioned medium when compared with control ( Supplementary Figure 8) . Our data suggest that in mammary cells, secreted SEMA3B could affect the behavior of neighboring cells by reducing their motility and cellular invasiveness.
Next, we examined the effect of GATA3 and SEMA3B interplay in cellular proliferation using a colony formation assay in twodimensional cultures. Overexpression of SEMA3B resulted in formation of fewer colonies when compared with control (Figures 3g and h) . Inhibition of cellular proliferation and colony formation in cells expressing SEMA3B mirrored MDA-GATA3 cells. Figure 7) . We observed similar behavior in mammary MCF7 tumor cells. Expression of SEMA3B significantly inhibited colony formation when compared with control. However, knockdown of SEMA3B even in presence of GATA3, rescued proliferative phenotype in MCF7 tumor cells ( Supplementary  Figures 9a and b) .
However, removal of SEMA3B in cells with intact GATA3 signaling restored cellular proliferation and colony formation (Figures 3g and h; Supplementary
Taken together, our in vitro data suggest that the presence of SEMA3B is pivotal for effective GATA3 signaling and intact GATA3/ SEMA3B signaling axis is essential for inhibition of abnormal cellular migration and proliferation.
Tumor-suppressive activity exerted by GATA3 requires intact SEMA3B expression
To determine the necessity of SEMA3B in GATA3 tumorsuppressive activity, we orthotopically transplanted the MDA-MB-231 stable cell lines via intra-mammary gland injection into 8week-old female nude mice. To examine the role of SEMA3B independent of GATA3 signaling in tumor growth, we compared control (SEMA3B-low) to MDA-SEMA3B (SEMA3B-high) cell transplants. Overexpression of SEMA3B reduced tumor growth and resulted in the formation of significantly smaller tumors when compared with control ( Figure 4a ). To further elaborate on the importance of SEMA3B as a signal transducer molecule downstream of GATA3, we also transplanted tumor cells expressing GATA3 with or without the intact SEMA3B molecule. Tumor cells overexpressing GATA3 demonstrated slower tumor growth and smaller tumor size. 17, 25, 26, 29, 31, 32 In our transplant experiments, analysis of tumor sizes indicated that MDA-GATA3-SEMA3B KD cells give rise to significantly larger tumors when compared with tumors from MDA-GATA3 cells. These results suggest the need for presence of SEMA3B for proper GATA3 tumor-suppressive activity (Figure 4b ). Thus, in vivo SEMA3B mimics GATA3 activity in hindering tumor growth. We also performed Ki67 staining to assess the cellular proliferation status of the tumor cells in our samples. Cells in control tumors stained strongly for Ki67, whereas MDA-GATA3 or MDA-SEMA3B tumors had many fewer Ki67positive cells (Figure 4c ). Sections from MDA-GATA3-Sema3B KD tumors had more intense Ki67 staining than MDA-GATA3 or MDA-SEMA3B tumor sections. Knockdown of SEMA3B in tumor cells expressing GATA3 restored the proliferative ability of tumor cells and support the observations that GATA3 relies on SEMA3B to transduce its tumor-suppressive activity (Figure 4c ).
SEMA3B decreases tumor metastasis
The most significant factor in breast cancer aggressiveness is its propensity to metastasize. Therefore, we asked whether SEMA3B regulated metastasis of MBA-MB-231 tumors. We investigated tumor cell metastasis to inguinal lymph nodes in the orthotopically transplanted mice. Mice with control MDA-MB-231 or MDA-SEMA3B KD tumors had significantly larger lymph nodes, larger lymph node metastatic colonies and higher number of metastatic cells in the lymph nodes than the mice with tumors expressing GATA3 or SEMA3B (Figures 4d and e ). Thus, our data suggest that SEMA3B can interfere with tumor metastasis.
Previous studies have indicated that semaphorins can regulate cell migration through Rho family of small GTPases. [4] [5] [6] [7] [8] [9] Recent reports indicate that LIM kinases (LIMK1 and LIMK2) that are downstream targets of Rho GTPases, have a role in enhancing breast cancer progression and metastasis. [33] [34] [35] [36] [37] As SEMA3B interferes with breast cancer progression, we asked whether SEMA3B influences LIMK1 and LIMK2 activity. Functional activation of LIM kinases requires phosphorylation at LIMK1 (threonine 508) and LIMK2 (threonine 505). 38, 39 We analyzed phospho-LIMK1/2 in control MDA-MB-231 and MDA-SEMA3B cells. Western blot analysis indicated that SEMA3B reduces phospho-LIMK1/2 levels when compared with control ( Figure 4f ). Reduction of phopho-LIMK1/2 suggests one potential mechanism whereby SEMA3B could inhibit breast cancer progression and metastasis.
Collectively, our experiments support the importance of SEMA3B as a component of GATA3 signaling axis in mammary cells and provide evidence that SEMA3B can inhibit tumor growth as well as tumor metastasis downstream of GATA3 signaling.
DISCUSSION
SEMA3B was originally identified as a neurite guidance molecule during nervous system development. However, recently, alternative roles for SEMA3B in non-neuronal adult cells have been described, highlighting the diverse functionality of developmental genes in an adult organism. In this study, we have shown that SEMA3B is a direct target of the transcription factor GATA3 and that loss of SEMA3B correlates with aggressive mammary tumor development and progression. GATA3 has a fundamental role in maintaining mammary gland homeostasis by promoting luminal epithelial cell differentiation and also acts as a tumor suppressor by transcriptional regulation to influence the expression of a plethora of genes including pro-tumor factors. 32 Our tumor transplant data indicate that overexpression of SEMA3B interferes with tumor metastasis similar to tumors expressing GATA3. By experimental analyses, we show that downregulation of SEMA3B leads to cellular proliferation, tumor growth and enhanced tumor invasiveness, even in presence of intact GATA3. We also show that SEMA3B inhibits tumor invasiveness by downregulating EMT-associated genes and increasing E-cadherin levels. In addition, we found that SEMA3B inhibits phosphorylation and subsequent activation of LIMK1/2. LIMK1/2 have been shown to promote breast cancer progression, therefore inhibition of LIMK1/2 is one potential mechanism for SEMA3B to exert inhibitory effects during breast cancer progression.
SEMA3B is a secreted molecule and it is important to consider its tumor-suppressive influence beyond its potential autocrine functions. We provide evidence that in mammary cells, SEMA3B could function in paracrine fashion to inhibit cellular migration and invasiveness. It is likely that other SEMA3B-producing cells in the tumor microenvironment could influence the behavior of tumor cells. Loss of SEMA3B expression in cells of tumor microenvironment, as well as tumor cells themselves could result in formation of aggressive breast cancer. To that extent, we hypothesize that the GATA3/SEMA3B signaling presents an important regulatory pathway that directs antitumor activity in the mammary gland.
The fact that a neuronal-specific gene such as SEMA3B could influence mammary gland homeostasis is intriguing, building on other examples of such diversity. For example, SLITs (slit guidance ligand) and their receptor ROBO (roundabout) were originally identified as axonal guidance signaling molecules during development, 40, 41 but have been shown to have alternative roles GATA3 controls SEMA3B expression in mammary cells P Shahi et al in mammary gland branching, 42 mammary stem cell selfrenewal 43 and breast cancer development. 44 Recently, GATA3 has emerged as one of top three genes associated with breast cancer development. Thus, uncovering new GATA3 signaling axes could help to better understand breast cancer development. Previously, we have shown that tumorsuppressive activity of GATA3 is partially mediated through direct upregulation of miR-29b. 32 miR-29b functions as a signal transducer of GATA3 and directs many antitumor activities via targeting a collection of genes that are involved in angiogenesis and remodeling the tumor microenvironment. Preliminary studies indicate that induction of SEMA3B via GATA3 is independent miR-29b. Our findings suggest that GATA3 induces multiple antitumor pathways to inhibit mammary tumor development. Redundant regulatory pathways could provide a safeguard for proper cellular functioning. The GATA3/SEMA3B signaling could function in parallel with other pathways such as GATA3/miR-29b to ensure proper cellular function in mammary epithelial cells.
There are several possibilities as to how lack of SEMA3B expression could override GATA3 activity. SEMA3B forms a complex with neuropilins and plexins on the cell surface. VEGF-A (vascular endothelial growth factor A) also binds to neuropilins and this complex promotes cellular migration. 45, 46 In tumor cells, upregulation of SEMA3B via GATA3 could push the competition for neuropilin binding to favor SEMA3B. In turn, elevated SEMA3B levels could outcompete VEGF-A for binding to neuropilins, thereby disrupting tumor cell migration. In addition, as SEMA3B can inhibit phosphatidylinositol 3-kinase/Akt, 47 upregulation of SEMA3B by GATA3 could result in downregulation of phosphatidylinositol 3-kinase/Akt activity and lead to inhibition of cellular proliferation and tumor growth.
Collectively, our data shed new insights into better understanding of GATA3 pathway in the mammary gland. We identified SEMA3B as a direct target of the GATA3 transcription factor and highlighted its importance as a signal transducer molecule. Loss of SEMA3B overrides GATA3's instructive ability to function as a tumor suppressor and designates SEMA3B as an integral part of GATA3 pathway in mammary epithelial cells. Our findings introduce SEMA3B as a molecular target that could potentially provide new therapeutic strategies against aggressive breast cancer.
MATERIALS AND METHODS
Cell culture and siRNA constructs T47D tumor cells (ATCC, Manassas, VA, USA) were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum, insulin and antibiotics. MDA-MB-231 cells (ATCC) were cultured in RPMI-1640 supplemented with 10% fetal bovine serum and antibiotics. EpH4.9 cells were cultured in DME-H21 medium supplemented with 5% fetal bovine, insulin (5 μg/ml) and antibiotics. Three-dimensional Matrigel culture assays were performed as described. 32 The lentiviral SEMA3B short hairpin RNA constructs were generous gift from Dr Luca Tamagnone. The purchased siRNA sequences were as follows: ON-TARGETplus GATA3 siRNA (Dharmacon, Lafayette, CO, USA). SEMA3B siRNA (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA).
Immunostaining, histology and antibodies
Immunofluorescence. Cells were cultured on coverslips before staining. Cells were washed with cold phosphate-buffered saline (PBS) and fixed with 4% paraformaldehyde for 20 min. Cells were washed with cold PBS and blocked with PBS, 5% goat serum and 0.25% Triton X-100 for at least 1 h at room temperature. Coverslips were incubated with primary antibody diluted in PBS plus 5% goat serum overnight at 4°C. Coverslips were washed with PBS and incubated with secondary antibody for 1 h at room temperature, then washed with PBS and mounted with Vectashield mounting medium with DAPI (Vector Laboratories, Burlingame, CA, USA).
Immunohistochemistry. Tissues were fixed in 4% paraformaldehyde overnight and embedded in paraffin. Tissues were sectioned into 5-7 μm sections and a standard protocol for hematoxylin and eosin staining was used for histological analysis. Immunostaining was performed using the sodium citrate protocol for antigen retrieval as previously described. 15 Images were captured using Nikon C1si confocal microscope (Nikon Instruments, Melville, NY, USA).
Antibodies. Actin-HRP (cs-47778, Santa Cruz Biotechnology Inc.), Alexa Fluor 546 goat anti-mouse (A-11008, ThermoFisher Scientific, San Jose, CA, USA), Alexa Fluor 488 goat anti-rabbit (A-11030, ThermoFisher Scientific), GATA3 (AF2605, R&D Systems, Minneapolis, MN, USA), Ki67 (ab15580, Abcam, Cambridge, MA, USA), Sema3B (sc-21204-R, Santa Cruz Biotechnology Inc.). Phoshop-LIMK1 (Thr508)/LIMK2 (Thr505) (3841T, Cell Signaling Technology, Danvers, MA, USA). LIMK1 (VMA00361KT, Bio-Rad Laboratories Inc., Hercules, CA, USA). LIMK2 (8C11) (3845, Cell Signaling Technology).
Bioinformatics and computational analysis SEMA3B expression analysis in human breast cancer and normal tissues was performed using the Oncomine database (www.oncomine.org). Statistical analysis was performed via Oncomine default algorithms. 48 The TCGA data set obtained from Oncomine is embedded in the TCGA database (https://tcga-data.nci.nih.gov/tcga). 49 Heatmaps were generated from breast cancer TCGA database. The GSE9014 data set obtained from Oncomine is embedded in NCBI GEO database (http://www.ncbi.nlm.nih. gov/geo) 50 for SEMA3B expression analysis.
Kaplan-Meier log-rank tests were performed using default parameters in SurvExpress (http://bioinformatica.mty.itesm.mx/SurvExpress). 51 Patient data were segregated into low or high SEMA3B expressing groups at the median expression value in all cases.
Promoter analysis and ChIP assay SEMA3B promoter analysis was performed using the ENCODE ChIP-Seq data set. Primer sequences for ChIP analysis: Set #1, 5′-AGACAG GTATGACCGTGACC-3′ (forward) and 5′-AGCTGTCTTGTGCTTGGGAAT-3′ (reverse); Set #2, 5′-CAGACCTCATGGGACGAGAC-3′ (forward) and 5′-TGG CTAGCTGTCTTGTGCTT-3′ (reverse). GATA3 and SEMA3B ChIP analysis was performed using the ChIP-IT High-Sensitivity Kit as per the manufacturer's protocol (Active Motif, Carlsbad, CA, USA).
Scratch assay
Cells were seeded in six-well plates at a density of 5 × 10 5 cells per well. After 24 h, a monolayer of cells was scratched by a 200-μl pipette tip. Cell migration was quantified by counting the number of cells that had migrated to the scratched area within 24 h.
Colony formation assay
Cells were seeded in six-well plates at a density of 1 × 10 3 cells per well and cultured for 14 days. Cells were fixed using methanol and stained with Giemsa solution and colonies were counted.
Animal studies
In all, 5 × 10 5 cells in 10 μl of 1:1 DMEM/Matrigel (BD Biosciences, San Jose, CA, USA) were injected in the fat pads of female 8-week-old nude mice (Simonsen Laboratories, Gilroy, CA, USA). Once palpable, tumors were measured twice weekly and the tumor volumes were determined as follows: V = 0.52 × (length) 2 × width. All mouse procedures were approved by University of California, San Francisco, Institutional Animal Care and Use Committee.
Statistical analysis
Statistical analysis was conducted using Prism 7 software (Graph Pad Software, Inc., San Diego, CA, USA). Statistical significance between two groups was calculated using Student's t-test, A one-way analysis of variance was performed to determine two or more group differences with Bonferroni test and P-values o 0.05 were considered significant.
